Prostate-specific antigen kinetics as a surrogate endpoint in clinical trials of metastatic castration-resistant prostate cancer: A review

Cancer Treatment Reviews

Volumn 38, Issue 8, 2012, Pages 1020-1026

  Colloca, G ^a  

^a ASL 1 Imperiese   (Italy)

Author keywords

Castration resistant prostate cancer; Growth rate constant; PSA doubling time; Surrogate endpoints

Indexed keywords

ADENOVIRUS VECTOR; ATRASENTAN; CYTOTOXIC AGENT; DASATINIB; DNA VACCINE; DOCETAXEL; ERLOTINIB; GEFITINIB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SIPULEUCEL T; SUNITINIB;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CASTRATION RESISTANT PROSTATE CANCER; CELL KINETICS; CIRCULATING TUMOR CELL; CLINICAL TRIAL (TOPIC); DRUG DOSE COMPARISON; GROWTH RATE; HUMAN; METASTASIS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR GROWTH;

BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; KINETICS; MALE; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84867139766     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.03.008     Document Type: Review

References (44)

1. Ferlay J., Parkin D.M., Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010, 46:765-781.
2. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. J Am Med Assoc 2005, 294:433-439.
3. Scher H.I., Heller G. Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology 2000, 55:323-327.
4. Vollmer R.T. Dissecting the dynamics of serum prostate-specific antigen. Am J Clin Pathol 2010, 133:187-193.
5. Brenner H., Arndt V. Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis. J Clin Oncol 2005, 23:441-447.
6. Groome P.A., Rohland S.L., Siemens D.R., et al. Assessing the impact of comorbid illnesses on death within 10 years in prostate cancer treatment candidates. Cancer 2011, 117(17):3943-3952.
7. Prentice R.L. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989, 8:431-440.
8. Fleming T.R. Surrogate endpoints and FDA's accelerated approval process. Health Affairs 2005, 24:67-78.
9. Armstrong A.J., Garrett-Mayer E., Yang Y.C.O., et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007, 25:3965-3970.
10. Petrylak D.P., Ankerst D.P., Jiang C.S., et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006, 98:516-521.
11. Fizazi K., De Bono J.S., Flechon A., et al. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer. Eur J Cancer 2012, 48(1):85-93.
12. Halabi S., Vogelzang N.J., Ou S.S., et al. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol 2009, 27:2766-2771.
13. Sonpavde G., Pond G.R., Berry W.R., et al. The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. Cancer 2011, 117:3963-3971.
14. Scher H.I., Halabi S., Tannock I., et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels ofr testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008, 26:1148-1159.
15. Kantoff P.W., Higano C.S., Shore N.D., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
16. Gulley J.L., Drake C.G. Immunotherapy for prostate cancer: recent advances, lesson learned, and areas for further research. Clin Cancer Res 2011, 17(12):3884-3891.
17. De Bono J.S., Scher H.I., Montgomery R.B., et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008, 14:6302-6309.
18. Dotan E., Cohen S.J., Alpaugh K.R., Meropol N.J. Circulating tumor cells: evolving evidence and future challenges. Oncologist 2009, 14:1070-1082.
19. Scher H.I., Jia X., de Bono J.S., et al. Circulating tumor cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 2009, 10:233-239.
20. Ponholzer A., Popper N., Breitenecker F., et al. Proposal for a standardized PSA doubling-time calculation. Anticancer Res 2010, 30:1633-1636.
21. Oudard S., Banu E., Scotte F., et al. Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann Oncol 2007, 18:1828-1833.
22. Stein W.D., Figg W.D., Dahut W., et al. Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data. Oncologist 2008, 13:1046-1054.
23. Stein W.D., Gulley J.L., Schlom J., et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 2011, 17:907-917.
24. Collette L., de Reijke T.M., Schroeder F.H. EORTC Genito-Urinary Group. Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892). Eur Urol 2008, 44:182-189.
25. Tomioka S., Shimbo M., Amiya Y., et al. Outcome of patients with hormone-refractory prostate cancer: prognostic significance of prostate-specific antigen-doubling time and nadir prostate-specific antigen. Jpn J Clin Oncol 2008, 38:36-42.
26. Daskivich T.J., Regan M.M., Oh W.K. Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy. Urology 2007, 70:527-531.
27. Armstrong A.J., Garrett-Mayer E.S., Yang Y.O., et al. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007, 13(21):6396-6403.
28. McNeel D.G., Dunphy E.J., Davies J.G., et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 2009, 27:4047-4054.
29. Smith M.R., Manola J., Kaufman D.S., et al. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer 2004, 101(7):1569-1574.
30. Schmid H.-P., Morant R., Bernhard J., et al. Prostate specific antigen doubling time as auxillary end point in hormone refractory prostatic carcinoma. Eur Urol 2003, 43:28-30.
31. Semeniuk R.C., Venner P.M., North S. Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer. Urology 2006, 68:565-569.
32. Hanninen M., Venner P., North S. A rapid PSA half-life following docetaxel chemotherapy is associated with improved survival in hormone refractory prostate cancer. Can Urol Assoc J 2009, 3:369-374.
33. Nelson J.B., Love W., Chin J.L., et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer. Cancer 2008, 113:2478-2487.
34. Carducci M.A., Saad F., Abrahamsson P.A., et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007, 110:1956-1966.
35. Higano C.S., Corman J.M., Smith D.C., et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogenic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008, 113:975-984.
36. Yu E.Y., Wilding G., Posadas E., et al. Phase II of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009, 15:7421-7428.
37. Canil C.M., Moore M.J., Winquist E., et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada - Clinical Trials Group. J Clin Oncol 2005, 23:455-460.
38. Sonpavde G., Periman P.O., Bernold D., Weckstein D., Fleming M.T., Galsky M.D., et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2010, 21:319-324.
39. Lubaroff D.M., Konety B.R., Link B., et al. Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin Cancer Res 2009, 15:7375-7380.
40. Gravis G., Bladou F., Salem N., et al. Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. Ann Oncol 2008, 19:1624-1628.
41. Nabhan C., Lestingi T.M., Galvez A., et al. Erlotinib has a moderate single-agent activity in chemotherapy-naïve castration-resistant prostate cancer: final results of a phase II trial. Urology 2009, 74:665-671.
42. Hildebrandt B., Sauer B., Kalis O., et al. Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells - a pilot study. Prostate 2007, 67:500-508.
43. Arlen P.M., Bianco F., Dahut W.L., et al. Prostate specific antigen working group guidelines on prostate specific antigen doubling time. J Urol 2008, 179:2181-2186.
44. Collette L. Prostate-specific antigen (PSA) as surrogate end point for survival in prostate cancer clinical trials. Eur Urol 2008, 53:6-9.